JP2020500523A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020500523A5 JP2020500523A5 JP2019528909A JP2019528909A JP2020500523A5 JP 2020500523 A5 JP2020500523 A5 JP 2020500523A5 JP 2019528909 A JP2019528909 A JP 2019528909A JP 2019528909 A JP2019528909 A JP 2019528909A JP 2020500523 A5 JP2020500523 A5 JP 2020500523A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- sequence
- acid sequence
- antigen recognition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 62
- 239000000427 antigen Substances 0.000 claims 37
- 108091007433 antigens Proteins 0.000 claims 37
- 102000036639 antigens Human genes 0.000 claims 37
- 108091008874 T cell receptors Proteins 0.000 claims 31
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 31
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 claims 20
- 210000004027 cell Anatomy 0.000 claims 17
- 108020004707 nucleic acids Proteins 0.000 claims 11
- 102000039446 nucleic acids Human genes 0.000 claims 11
- 150000007523 nucleic acids Chemical class 0.000 claims 11
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- 239000013598 vector Substances 0.000 claims 10
- 210000001744 T-lymphocyte Anatomy 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 239000012634 fragment Substances 0.000 claims 4
- 230000002062 proliferating effect Effects 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 150000001413 amino acids Chemical class 0.000 claims 3
- 239000012472 biological sample Substances 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 206010004593 Bile duct cancer Diseases 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 2
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims 2
- 101001005728 Homo sapiens Melanoma-associated antigen 1 Proteins 0.000 claims 2
- 102100025050 Melanoma-associated antigen 1 Human genes 0.000 claims 2
- 208000002030 Merkel cell carcinoma Diseases 0.000 claims 2
- 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 claims 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 2
- 208000026900 bile duct neoplasm Diseases 0.000 claims 2
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 2
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 claims 2
- 238000003745 diagnosis Methods 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 201000004101 esophageal cancer Diseases 0.000 claims 2
- 210000000232 gallbladder Anatomy 0.000 claims 2
- 201000010175 gallbladder cancer Diseases 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 201000010536 head and neck cancer Diseases 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 2
- 238000009169 immunotherapy Methods 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 206010046766 uterine cancer Diseases 0.000 claims 2
- 108091026890 Coding region Proteins 0.000 claims 1
- 230000000890 antigenic effect Effects 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 230000002068 genetic effect Effects 0.000 claims 1
- 210000002865 immune cell Anatomy 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000003780 insertion Methods 0.000 claims 1
- 230000037431 insertion Effects 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000002243 precursor Substances 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 238000000746 purification Methods 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022006308A JP2022068152A (ja) | 2016-12-08 | 2022-01-19 | 新規ｔ細胞受容体およびそれを用いた免疫療法 |
| JP2024114654A JP2024153696A (ja) | 2016-12-08 | 2024-07-18 | 新規ｔ細胞受容体およびそれを用いた免疫療法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662431588P | 2016-12-08 | 2016-12-08 | |
| DE102016123847.3A DE102016123847B3 (de) | 2016-12-08 | 2016-12-08 | Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie |
| US62/431,588 | 2016-12-08 | ||
| DE102016123847.3 | 2016-12-08 | ||
| PCT/EP2017/081800 WO2018104438A1 (en) | 2016-12-08 | 2017-12-07 | Novel t cell receptors and immune therapy using the same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022006308A Division JP2022068152A (ja) | 2016-12-08 | 2022-01-19 | 新規ｔ細胞受容体およびそれを用いた免疫療法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020500523A JP2020500523A (ja) | 2020-01-16 |
| JP2020500523A5 true JP2020500523A5 (enExample) | 2020-07-30 |
| JP7016543B2 JP7016543B2 (ja) | 2022-02-07 |
Family
ID=60990744
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019528909A Active JP7016543B2 (ja) | 2016-12-08 | 2017-12-07 | 新規ｔ細胞受容体およびそれを用いた免疫療法 |
| JP2022006308A Pending JP2022068152A (ja) | 2016-12-08 | 2022-01-19 | 新規ｔ細胞受容体およびそれを用いた免疫療法 |
| JP2024114654A Withdrawn JP2024153696A (ja) | 2016-12-08 | 2024-07-18 | 新規ｔ細胞受容体およびそれを用いた免疫療法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022006308A Pending JP2022068152A (ja) | 2016-12-08 | 2022-01-19 | 新規ｔ細胞受容体およびそれを用いた免疫療法 |
| JP2024114654A Withdrawn JP2024153696A (ja) | 2016-12-08 | 2024-07-18 | 新規ｔ細胞受容体およびそれを用いた免疫療法 |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US10702609B2 (enExample) |
| EP (1) | EP4032544A3 (enExample) |
| JP (3) | JP7016543B2 (enExample) |
| KR (3) | KR20220038511A (enExample) |
| AU (1) | AU2024227729A1 (enExample) |
| CL (2) | CL2019001535A1 (enExample) |
| CO (1) | CO2019006914A2 (enExample) |
| CY (1) | CY1124997T1 (enExample) |
| DK (1) | DK3551221T3 (enExample) |
| ES (1) | ES2916092T3 (enExample) |
| HR (1) | HRP20220131T8 (enExample) |
| HU (1) | HUE058957T2 (enExample) |
| IL (1) | IL267129A (enExample) |
| LT (1) | LT3551221T (enExample) |
| MD (1) | MD3551221T2 (enExample) |
| MX (1) | MX2022015821A (enExample) |
| MY (1) | MY192819A (enExample) |
| NZ (1) | NZ754365A (enExample) |
| PH (1) | PH12019501241A1 (enExample) |
| PL (1) | PL3551221T3 (enExample) |
| PT (1) | PT3551221T (enExample) |
| RS (1) | RS62865B1 (enExample) |
| SI (1) | SI3551221T1 (enExample) |
| TW (1) | TWI803910B (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012104843A1 (en) | 2011-02-06 | 2012-08-09 | Yeda Research And Development Co.Ltd. At The Weizmann Institute Of Science | Affinity maturated t cell receptors and use thereof |
| WO2016145578A1 (en) | 2015-03-13 | 2016-09-22 | Syz Cell Therapy Co. | Methods of cancer treatment using activated t cells |
| GB201520570D0 (en) * | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| DE102016123847B3 (de) * | 2016-12-08 | 2018-04-05 | Immatics Biotechnologies Gmbh | Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie |
| MD3551221T2 (ro) * | 2016-12-08 | 2022-04-30 | Immatics Biotechnologies Gmbh | Noi receptori de celule T și imunoterapie cu utilizarea acestora |
| WO2019183924A1 (en) | 2018-03-30 | 2019-10-03 | Syz Cell Therapy Co. | Improved multiple antigen specific cell therapy methods |
| WO2019196088A1 (en) | 2018-04-13 | 2019-10-17 | Syz Cell Therapy Co. | Methods of obtaining tumor-specific t cell receptors |
| KR20220029584A (ko) | 2019-05-27 | 2022-03-08 | 이매틱스 유에스 인코포레이티드 | 바이러스 벡터 및 입양 세포 요법에서 그 사용 |
| JP2023515131A (ja) | 2020-02-24 | 2023-04-12 | イマティクス ユーエス，アイエヌシー． | がんおよび関連する悪性腫瘍の治療のためにｔ細胞を増殖させる方法 |
| WO2022040631A1 (en) | 2020-08-21 | 2022-02-24 | Immatics US, Inc. | Methods for isolating cd8+ selected t cells |
| DE102021100038A1 (de) | 2020-12-31 | 2022-06-30 | Immatics US, Inc. | Modifizierte cd8-polypeptide, zusammensetzungen und verfahren zu deren verwendung |
| CR20230295A (es) | 2020-12-31 | 2023-07-27 | Immatics Us Inc | Polipéptidos cd8, composiciones y métodos de uso de estos |
| US20230089392A1 (en) | 2021-09-20 | 2023-03-23 | Immatics US, Inc. | Monocyte depletion of t cells populations for t-cell therapy |
| CN118525037A (zh) * | 2021-10-29 | 2024-08-20 | 侯亚非 | 识别ctnnb1中s37f突变的t细胞受体及其应用 |
| US20230142468A1 (en) | 2021-11-08 | 2023-05-11 | Immatics US, Inc. | Methods for generating cell spheroids |
| EP4463549A2 (en) | 2022-01-14 | 2024-11-20 | Tune Therapeutics, Inc. | Compositions, systems, and methods for programming t cell phenotypes through targeted gene repression |
| US20250134999A1 (en) | 2022-01-14 | 2025-05-01 | Tune Therapeutics, Inc. | Compositions, systems, and methods for programming t cell phenotypes through targeted gene activation |
| US20230348561A1 (en) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | Dominant negative tgfbeta receptor polypeptides, cd8 polypeptides, cells, compositions, and methods of using thereof |
| WO2023212655A1 (en) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof |
| KR20250018168A (ko) | 2022-04-28 | 2025-02-04 | 이매틱스 유에스 인코포레이티드 | 막-결합된 il-15, cd8 폴리펩티드, 세포, 조성물, 및 이의 사용 방법 |
| EP4519418A1 (en) | 2022-05-05 | 2025-03-12 | Immatics US, Inc. | Methods for improving t cell efficacy |
| JP2024012879A (ja) * | 2022-07-19 | 2024-01-31 | 国立大学法人三重大学 | 腫瘍反応性ｔ細胞の製造方法 |
| JP2025531268A (ja) | 2022-09-19 | 2025-09-19 | チューン セラピューティクス インコーポレイテッド | Ｔ細胞機能を調節するための組成物、システム、および方法 |
| EP4754248A1 (en) | 2023-07-31 | 2026-06-10 | Tune Therapeutics, Inc. | Compositions and methods for multiplexed activation and repression of t cell gene expression |
| CN121909284A (zh) | 2023-07-31 | 2026-04-21 | 图恩疗法股份有限公司 | 用于调节il-2基因表达的组合物和方法 |
| US20250134931A1 (en) | 2023-11-01 | 2025-05-01 | Immatics US, Inc. | Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof |
| CN117624340B (zh) * | 2024-01-23 | 2024-04-30 | 北京臻知医学科技有限责任公司 | 识别人乙型肝炎病毒（hbv）抗原的t细胞受体（tcr）及其用途 |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
| US20020150891A1 (en) | 1994-09-19 | 2002-10-17 | Leroy E. Hood | Diagnostic and therapeutic compositions and methods which utilize the t cell receptor beta gene region |
| US5714352A (en) | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
| WO2001058479A1 (en) | 2000-02-08 | 2001-08-16 | The Penn State Research Foundation | Immunotherapy using interleukin 13 receptor subunit alpha 2 |
| CN102272153B (zh) * | 2008-11-24 | 2015-04-15 | 德国慕尼黑亥姆霍兹研究中心健康和环境有限公司 | 高亲和力t细胞受体及其应用 |
| US9345748B2 (en) | 2010-09-21 | 2016-05-24 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-SSX-2 T cell receptors and related materials and methods of use |
| SI2755997T1 (sl) | 2011-09-15 | 2018-11-30 | The United States of America, as represented by Secretary, Department of Health and Human Services, Office of Technology Transfer, National Institutes of Health | T-celični receptorji, ki prepoznajo HLA-A1- ali HLA-CW7-omejeni mage |
| PT2951202T (pt) * | 2013-01-29 | 2020-07-07 | Max Delbruck Centrum Fur Molekulare Medizin Mdc Berlin Buch | Moléculas de ligação de alta avidez que reconhecem mage-a1 |
| DK2971045T3 (da) | 2013-03-13 | 2019-09-16 | Health Research Inc | Sammensætninger og fremgangsmåder til anvendelse af rekombinante T-celle-receptorer til direkte genkendelse af tumorantigen |
| CA2912389C (en) | 2013-06-10 | 2020-01-28 | The General Hospital Corporation D/B/A Massachusetts General Hospital | Methods and compositions for reducing immunosupression by tumor cells |
| US10202640B2 (en) * | 2014-05-07 | 2019-02-12 | The Board Of Trustees Of The Leland Stanford Junior University | Single cell analysis of T cells using high-throughput multiplex amplification and deep sequencing |
| US10738278B2 (en) | 2014-07-15 | 2020-08-11 | Juno Therapeutics, Inc. | Engineered cells for adoptive cell therapy |
| US20170335290A1 (en) | 2014-10-31 | 2017-11-23 | Baylor College Of Medicine | Survivin specific t-cell receptor targeting tumor but not t cells |
| US20220280564A1 (en) | 2014-11-21 | 2022-09-08 | Immatics US, Inc. | Methods for expanding t cells for the treatment of cancer and related malignancies |
| CN105316362B (zh) | 2015-08-19 | 2020-03-17 | 暨南大学 | 一种Dual-RMCE介导的TCR基因置换系统及其方法 |
| JP6895975B2 (ja) | 2016-01-06 | 2021-06-30 | ヘルス リサーチ インコーポレイテッドＨｅａｌｔｈ Ｒｅｓｅａｒｃｈ， Ｉｎｃ． | 組換えｔ細胞受容体を含む組成物及びライブラリー並びに組換えｔ細胞受容体を使用する方法 |
| EP4086285A1 (en) | 2016-02-25 | 2022-11-09 | Cell Medica Switzerland AG | Binding members to pd-l1 |
| GB201604492D0 (en) * | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Transfected t-cells and t-cell receptors for use in immunotherapy against cancers |
| CN106749620B (zh) | 2016-03-29 | 2020-09-25 | 广东香雪精准医疗技术有限公司 | 识别mage-a1抗原短肽的t细胞受体 |
| WO2017180587A2 (en) | 2016-04-11 | 2017-10-19 | Obsidian Therapeutics, Inc. | Regulated biocircuit systems |
| JP6989138B2 (ja) * | 2016-06-17 | 2022-01-05 | メディジーン イミュノテラピーズ ゲーエムベーハー | Ｔ細胞受容体及びその使用 |
| MD3551221T2 (ro) * | 2016-12-08 | 2022-04-30 | Immatics Biotechnologies Gmbh | Noi receptori de celule T și imunoterapie cu utilizarea acestora |
| DE102016123893A1 (de) | 2016-12-08 | 2018-06-14 | Immatics Biotechnologies Gmbh | T-Zellrezeptoren mit verbesserter Bindung |
| DE102016123847B3 (de) * | 2016-12-08 | 2018-04-05 | Immatics Biotechnologies Gmbh | Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie |
| US11702459B2 (en) | 2017-03-07 | 2023-07-18 | Universität Basel | MR1 restricted T cell receptors for cancer immunotherapy |
| AU2018234830B2 (en) * | 2017-03-15 | 2023-03-02 | Fred Hutchinson Cancer Center | High affinity MAGE-A1-specific TCRs and uses thereof |
| JP7391015B2 (ja) | 2017-09-29 | 2023-12-04 | アメリカ合衆国 | Ｐ５３がん特異的変異に対して抗原特異性を有するｔ細胞を単離する方法 |
| IL273515B2 (en) | 2017-09-29 | 2026-03-01 | Us Health | T cell receptors that recognize mutated P53 |
| KR20200119840A (ko) | 2018-02-09 | 2020-10-20 | 이매틱스 유에스 인코포레이티드 | T 세포의 제조 방법 |
| DE102018108612A1 (de) | 2018-03-21 | 2019-09-26 | Immatics US, Inc. | Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen |
| GB201804724D0 (en) | 2018-03-23 | 2018-05-09 | Univ Oslo Hf | Method of diagnosing cceliac disease |
| KR102892744B1 (ko) | 2018-04-19 | 2025-11-28 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | Mage-b2 특이성을 갖는 t 세포 수용체 및 이의 용도 |
| EA202091977A1 (ru) | 2018-05-28 | 2021-02-09 | Драгонфлай Терапьютикс, Инк. | Мультиспецифические связывающие белки, которые связывают cd33, nkg2d и cd16, и способы применения |
| US20220339271A1 (en) | 2018-09-12 | 2022-10-27 | Universität Basel | Mr1 restricted t cell receptors for cancer immunotherapy |
| CN113454110B (zh) | 2018-10-23 | 2024-07-02 | 里珍纳龙药品有限公司 | Ny-eso-1 t细胞受体和其使用方法 |
| GB201817821D0 (en) | 2018-10-31 | 2018-12-19 | Ospedale San Raffaele Srl | TCR and peptides |
| GB2613715B (en) | 2019-02-20 | 2023-12-06 | Fred Hutchinson Cancer Center | Binding proteins specific for RAS neoantigens and uses thereof |
| WO2020180648A1 (en) | 2019-03-01 | 2020-09-10 | Gritstone Oncology, Inc. | Selection of t cell receptors |
| CA3132434A1 (en) | 2019-03-04 | 2020-09-10 | University Health Network | T cell receptors and methods of use thereof |
| BR112021017744A2 (pt) | 2019-03-08 | 2021-11-16 | Obsidian Therapeutics Inc | Composições e métodos de cd40l para regulação ajustável |
| BR112021017703A8 (pt) | 2019-03-11 | 2023-04-18 | Hutchinson Fred Cancer Res | Receptores de células t wt1 de alta avidez e usos dos mesmos |
| US20200297768A1 (en) | 2019-03-19 | 2020-09-24 | Immatics US, Inc. | Cd28 t cell cultures, compositions, and methods of using thereof |
| US20200318068A1 (en) | 2019-04-04 | 2020-10-08 | Immatics US, Inc. | Use of retinoic acid in t-cell manufacturing |
| US20220213167A1 (en) | 2019-05-03 | 2022-07-07 | Gigamune, Inc. | Engineered cells expressing anti-tumor t cell receptors and methods of use thereof |
| KR20220029584A (ko) | 2019-05-27 | 2022-03-08 | 이매틱스 유에스 인코포레이티드 | 바이러스 벡터 및 입양 세포 요법에서 그 사용 |
| AU2020286756A1 (en) | 2019-06-06 | 2022-01-27 | Immatics Biotechnologies Gmbh | Sorting with counter selection using sequence similar peptides |
| US20210032370A1 (en) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Recruiting agent further binding an mhc molecule |
| US12480958B2 (en) | 2019-08-13 | 2025-11-25 | Immatics Biotechnologies Gmbh | Method for the characterization of peptide:MHC binding polypeptides |
| DE102020111571A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| WO2022040631A1 (en) | 2020-08-21 | 2022-02-24 | Immatics US, Inc. | Methods for isolating cd8+ selected t cells |
| US12234473B2 (en) | 2020-12-31 | 2025-02-25 | Immatics US, Inc. | CD8 polypeptides, compositions, and methods of using thereof |
-
2017
- 2017-12-07 MD MDE20191170T patent/MD3551221T2/ro not_active IP Right Cessation
- 2017-12-07 HU HUE17829609A patent/HUE058957T2/hu unknown
- 2017-12-07 PL PL17829609T patent/PL3551221T3/pl unknown
- 2017-12-07 HR HRP20220131TT patent/HRP20220131T8/hr unknown
- 2017-12-07 RS RS20220094A patent/RS62865B1/sr unknown
- 2017-12-07 LT LTEPPCT/EP2017/081800T patent/LT3551221T/lt unknown
- 2017-12-07 NZ NZ754365A patent/NZ754365A/en not_active IP Right Cessation
- 2017-12-07 DK DK17829609.1T patent/DK3551221T3/da active
- 2017-12-07 SI SI201731045T patent/SI3551221T1/sl unknown
- 2017-12-07 KR KR1020227008109A patent/KR20220038511A/ko not_active Abandoned
- 2017-12-07 MY MYPI2019002714A patent/MY192819A/en unknown
- 2017-12-07 EP EP21207265.6A patent/EP4032544A3/en active Pending
- 2017-12-07 KR KR1020247000927A patent/KR20240007775A/ko not_active Ceased
- 2017-12-07 KR KR1020217026811A patent/KR102375218B1/ko active Active
- 2017-12-07 ES ES17829609T patent/ES2916092T3/es active Active
- 2017-12-07 JP JP2019528909A patent/JP7016543B2/ja active Active
- 2017-12-07 PT PT178296091T patent/PT3551221T/pt unknown
- 2017-12-08 TW TW110126570A patent/TWI803910B/zh not_active IP Right Cessation
-
2019
- 2019-05-03 US US16/403,003 patent/US10702609B2/en active Active
- 2019-06-04 PH PH12019501241A patent/PH12019501241A1/en unknown
- 2019-06-05 IL IL26712919A patent/IL267129A/en unknown
- 2019-06-05 CL CL2019001535A patent/CL2019001535A1/es unknown
- 2019-06-07 MX MX2022015821A patent/MX2022015821A/es unknown
- 2019-06-27 CO CONC2019/0006914A patent/CO2019006914A2/es unknown
-
2020
- 2020-03-23 US US16/826,946 patent/US11998607B2/en active Active
-
2021
- 2021-11-12 CL CL2021002997A patent/CL2021002997A1/es unknown
-
2022
- 2022-01-19 JP JP2022006308A patent/JP2022068152A/ja active Pending
- 2022-01-27 CY CY20221100071T patent/CY1124997T1/el unknown
-
2024
- 2024-04-23 US US18/642,871 patent/US20240285779A1/en active Pending
- 2024-07-18 JP JP2024114654A patent/JP2024153696A/ja not_active Withdrawn
- 2024-10-29 AU AU2024227729A patent/AU2024227729A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020511936A5 (enExample) | ||
| HRP20220131T1 (hr) | Nova terapija s t-staničnim receptorima i imunološka terapija koja koristi iste | |
| CN105384825B (zh) | 一种基于单域抗体的双特异性嵌合抗原受体及其应用 | |
| JP2024105296A5 (enExample) | ||
| US12168061B2 (en) | Antibody against glypican-3 and application thereof | |
| FI3707159T3 (fi) | Uusia muokattuja t-solureseptoreita ja niitä käyttävä immuuniterapia | |
| IL274595B2 (en) | Antibodies specific to beta-tgf | |
| JP2020529830A5 (enExample) | ||
| CN103304638B (zh) | 具有抗肿瘤活性的pd-l1亲和肽及其应用 | |
| HRP20241228T1 (hr) | T stanični receptori i imunološka terapija uporabom istih protiv pram pozitivnih karcinoma | |
| JP2019512242A5 (enExample) | ||
| BR112019027291A2 (pt) | receptores de células t, molécula de fusão anti-cd3 de tcr, ácido nucleico, vetor de expressão, célula, composição farmacêutica, método de tratar um sujeito humano que tem câncer, formulação injetável para administrar a um sujeito humano e método de produzir um tcr | |
| JP2020512019A5 (enExample) | ||
| JP2021508255A5 (enExample) | ||
| JP2010110329A5 (enExample) | ||
| JP2016505635A5 (enExample) | ||
| WO2016180982A1 (en) | T cell recruiting polypeptides based on cd3 reactivity | |
| CN106467573A (zh) | 抗间皮素全人抗体以及靶向间皮素的免疫效应细胞 | |
| CN104853765A (zh) | 肿瘤特异性t细胞受体 | |
| JP2014530009A5 (enExample) | ||
| JP2015527070A5 (enExample) | ||
| WO2016053338A1 (en) | Methods of isolating t cell receptors having antigenic specificity for a cancer-specific mutation | |
| JP7012364B2 (ja) | Ｔ細胞受容体の認識機構を用いたがん又は感染症の治療及び診断 | |
| EP4412642A2 (en) | Indications for anti prame binders | |
| Chao et al. | Effector T cell responses unleashed by regulatory T cell ablation exacerbate oral squamous cell carcinoma |